LIANA-I: Pilot Study on Device-assisted Mobilisation of Critically Ill Patients

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05716451
Collaborator
(none)
40
1
2
22.5
1.8

Study Details

Study Description

Brief Summary

This Pilot study will hypothesize that patients with organ insufficiency and breathing assistance in our post-anaesthesia care unit (PACU) and ICU will be mobilized more often to an ICU mobility scale (IMS) ≥ 4 (i.e. standing) using the Liana® mobilizer. Therefore a randomized controlled pilot study will be conducted. The aim is to achieve an important physical function mile stone more often using this device.

Secondary hypotheses are:
  1. The intervention will relieve the burden of the health care staff in the unit

  2. The intervention will positively influence the functional outcome of critically ill patients

  3. The intervention is perceived as positive by the patients

Condition or Disease Intervention/Treatment Phase
  • Device: Device-assisted mobilisation with the sit/stand stabilizer Liana
N/A

Detailed Description

Patients who have been treated in the ICU for a prolonged period of time often have a high degree of immobility. In this context, a state of generalized weakness associated with muscle atrophy (ICUAW) develops in approximately 40% of ICU patients. The severity of generalized weakness may be individual in each patient. It is certain that especially elderly patients and patients with prolonged immobilization have an increased incidence of ICUAW. Symptoms can be highly variable depending on the severity of the course. Some patients report weakness of the extremities to paresis and weakness of the respiratory muscles. Weakness of the respiratory musculature can lead to a prolonged weaning process of mechanical ventilation, prolonging the stay in the ICU. Functional impairments due to ICUAW may also persist many years after the ICU stay. If ICUAW is diagnosed promptly, outcome can be improved by targeted early mobilization. Early mobilization is defined as mobilization in the first 72 h from ICU admission. However, there are numerous barriers to the implementation of early mobilization in critically ill patients, so this remains a major challenge.

Various studies have shown that patients can benefit from a high level of mobilization. For example, Scheffenbichler et al. showed that a high dose of mobilization was associated with increased independence of patients after discharge. The level of mobilization showed positive effects not only in this study, but also in Paton and colleagues. They were able to show that achieving a higher level of mobility (according to the Intensive Care Mobility Scale) was associated with improved outcome at six months. They found that achieving a higher level of mobilization positively affected the health status of patients, whereas increasing the number of mobilizations did not.

With device-assisted mobilization, patients could be mobilized to standing position early and more frequently. The aim of this pilot study is to test whether mobilization of critically ill patients with ventilatory support using device-assisted mobilization leads to increased mobilization to standing (IMS 4) or beyond.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomised Pilot Study on Device-assisted Mobilisation With a Sit/Stand Stabiliser of Critically Ill Patients With Ventilatory Support
Anticipated Study Start Date :
Feb 15, 2023
Anticipated Primary Completion Date :
May 30, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

Mobilization incl. support by the Liana. In the intervention group, Liana is used to train trunk stability in a sitting position. If this is successful, the patient is trained to stand. Mobilization to higher levels is performed according to clinical standards.

Device: Device-assisted mobilisation with the sit/stand stabilizer Liana
Non-invasive device-assisted mobilisation with LIANA

No Intervention: Control Group

Standard of Care without the use of the Liana. In the control group the therapy is carried out according to the ward standard without using the Liana.

Outcome Measures

Primary Outcome Measures

  1. Level of mobilisation (IMS) [28 Days]

    Mean level of mobilisation measured with the Intensive Car Unit Mobility Scale (IMS) till ICU discharge (or Day 28); IMS ranges from 0 (no mobilization) to 10 (independent walking)

Secondary Outcome Measures

  1. Frequency of IMS ≥ 4 [28 Days]

    Frequency of Days with IMS ≥ 4 till ICU discharge (or Day 28)

  2. Handgrip strength [28 Days]

    Muscle strength measured using handgrip strength till ICU discharge (or Day 28)

  3. MRC Sum Score [28 Days]

    Muscle strength measured using Medical Research Council (MRC) Sum Score till ICU discharge (or Day 28); MRC Sum Score ranges from 0 to 60, with 0 worst value

  4. Diaphragma function [28 Days]

    Diaphragm function by diaphragmatic thickening fraction using ultrasound till ICU discharge (or Day 28)

  5. CPAx Score [28 Days]

    The Chelsea Critical Care Physical Assessment Tool (CPAx) during the ICU stay (or till Day 28); ranging from 0 to 50 with 0 the worst score

  6. Trunk Control Test [28 Days]

    Trunk stability using the trunk control test during the ICU stay (or till Day 28)

  7. Duration of MV [180 Days]

    Duration of mechanical ventilation (MV) in days

  8. Patient satisfaction with VRS [28 Days]

    Patient satisfaction with mobilisation using a verbal rating scale (VRS 0-10), 0 the worst score

  9. Staff satisfaction with VRS [28 Days]

    Staff satisfaction with mobilisation using a verbal rating scale (VRS 0-10), 0 being worst score

  10. Staff binding time [28 Days]

    Staff binding time for mobilisation during the ICU stay (or Day 28)

  11. ICU LOS [180 Days]

    ICU length of stay in Days

  12. Hospital LOS [180 Days]

    Hospital length of stays

  13. Time in rehabilitation and hospital [180 Days]

    Time in rehabilitation facilities or hospital in days

  14. (I)ADL [180 Days]

    (Intrumental) Activities of Daily Living Score as measured by Iwashyna et al.; range 0-11, 0 the worst

  15. Disability [180 Days]

    Disability measured with the WHODAS 2.0 score

  16. Quality of life [180 Days]

    Quality of life measured with the EQ-5D-5L. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Detail information is available at https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/

  17. Physical Function [180 Days]

    Physical function measured with the Barthel Score, scoring from 0-100 with 0 the worst

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Intensive care patient with ventilatory support and an expected intensive care stay of at least another 48 h

  • Age ≥ 18 years

  • Current length of intensive care stay < 48 h

Exclusion Criteria:
  • Moribund and critically ill

  • Suspected 6-month mortality > 75%.

  • Increased intracranial pressure

  • Critically ill after cardiopulmonary resuscitation

  • Critically ill with primary neuromuscular disease or motor neuron disease

  • One or more amputated extremities

  • Patients, within 2h after surgery

  • Unstable fractures

  • Severe traumatic brain injury (e.g., brain and skull injuries)

  • Circulatory instability with norepinephrine > 0.3 µg/kg/min

  • Patients for whom there is an indication for deep sedation (RASS -5)

  • Language barrier

  • Fitting of legs into leg trays is not possible due to e.g. patient weight

Contacts and Locations

Locations

Site City State Country Postal Code
1 Charité - Univiversitätsmedizin Berlin Berlin Germany 10117

Sponsors and Collaborators

  • Charite University, Berlin, Germany

Investigators

  • Principal Investigator: Stefan J Schaller, MD, Charite University, Berlin, Germany

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stefan J Schaller, Deputy Clinical Director, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT05716451
Other Study ID Numbers:
  • LIANA-I
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 9, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Stefan J Schaller, Deputy Clinical Director, Charite University, Berlin, Germany
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2023